← Oncology Approval Tracker

FDA DECISION ·

Retevmo

selpercatinib · Eli Lilly

Traditional approvalTraditional conversionThyroid cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients aged 2 years and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and refractory to radioactive iodine when it is appropriate.

LAMPGEN ANALYSIS

Why it matters

The action converted the RET fusion-positive thyroid indication to traditional approval and included younger patients.

What research teams should watch

Record iodine treatment history or why it is inappropriate and distinguish RET fusion testing from RET mutation testing.

PRIMARY RECORDS

Sources